SCHEMBL20604693

SCHEMBL20604693

COc1ccc(-n2ccc3cc(C#N)ccc32)cc1

nearest known ligand 0.57

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 2/20 0.48
CDC7 O00311 2/20 0.47
CYP19A1 P11511 2/20 0.46
TDP2 O95551 1/20 0.46
FFAR4 Q5NUL3 1/20 0.46
ENPP3 O14638 1/20 0.44
CDK2 P24941 1/20 0.41
ROCK1 Q13464 1/20 0.41
PTGER2 P43116 1/20 0.41
HPGDS O60760 1/20 0.40
PDGFRB P09619 1/20 0.40
PDGFRA P16234 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
MAPKAPK2 P49137 1/20 0.40
KCNH2 Q12809 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20604584 0.85 FFAR4 (0.49) KDM1ACDC7CYP19A1FFAR4ENPP3
SCHEMBL10193341 0.83 ROCK1 (0.55) ROCK1PDGFRBPDGFRAL3MBTL1KCNH2
SCHEMBL12069041 0.82 SCN9A (0.52) CDC7CYP19A1TDP2FFAR4ENPP3
SCHEMBL10637458 0.82 EGFR (0.46) KDM1ACDC7TDP2ENPP3CDK2
SCHEMBL22359855 0.81 FFAR4 (0.53) CDC7CYP19A1FFAR4ENPP3CDK2
SCHEMBL6583376 0.81 KCNH2 (0.56) CDC7CYP19A1TDP2FFAR4ENPP3
SCHEMBL4282844 0.80 ENPP3 (0.56) CDC7CYP19A1TDP2FFAR4ENPP3
SCHEMBL20604726 0.80 FFAR4 (0.44) CDC7CYP19A1FFAR4ENPP3CDK2
SCHEMBL20025721 0.78 L3MBTL1 (0.44) KDM1ACYP19A1TDP2L3MBTL1
SCHEMBL15228837 0.78 CDC7 (0.45) CDC7CYP19A1FFAR4ENPP3CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3423443-B1 CYANO-SUBSTITUTED INDOLE COMPOUNDS AND USES THEREOF AS LSD1 INHIBITORS NOVARTIS AG (CH) 2020-08-19 EP disclosed
US-10590079-B2 Cyano-substituted indoles as LSD1 inhibitors NOVARTIS AG (CH) 2020-03-17 US disclosed
CN-110267945-A The benzazolyl compounds that cyano replaces and its purposes as LSD1 inhibitor 诺华股份有限公司 2019-09-20 CN disclosed
US-20190092724-A1 CYANO-SUBSTITUTED INDOLE COMPOUNDS AND USES THEREOF AS LSD1 INHIBITORS NOVARTIS AG (CH) 2019-03-28 US disclosed
US-20190092724-A1 CYANO-SUBSTITUTED INDOLE COMPOUNDS AND USES THEREOF AS LSD1 INHIBITORS NOVARTIS AG (CH) 2019-03-28 US disclosed
EP-3423443-A1 CYANO-SUBSTITUTED INDOLE COMPOUNDS AND USES THEREOF AS LSD1 INHIBITORS Novartis AG (CH) 2019-01-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10590079-B2 Cyano-substituted indoles as LSD1 inhibitors KDM1A, KDM1B, KDM3A KDM1A 1/4885CDC7 1070/4885CYP19A1 339/4885
US-20190092724-A1 CYANO-SUBSTITUTED INDOLE COMPOUNDS AND USES THEREOF AS LSD1 INHIBITORS KDM1A, KDM1B, KDM2A KDM1A 1/4885CDC7 1316/4885CYP19A1 212/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.